Trial readout calendar
Industry-sponsored Phase 2/3 trials whose primary completion date falls in the window, soonest first. Sponsor-reported in ClinicalTrials.gov; est. dates often slip, and top-line results usually follow weeks to months later. Tickers are matched by name with a confidence score. Each row links to the registry record. Not investment advice.
Window 2026-10-28 to 2027-01-26 - 934 trials - generated 2026-10-28T18:41:35Z - JSON
| Readout | Phase | Sponsor | Trial | Conditions |
|---|---|---|---|---|
| 2026-10-28 est. | P2/P3 | Hoffmann-La Roche | NCT05115110 A Study to Investigate the Safety and Efficacy of RO7204239 in Combination With Risdiplam (RO7034067) in Participants With Spinal Muscular A | Spinal Muscular Atrophy (SMA) |
| 2026-10-28 est. | P3 | Merck Sharp & Dohme LLC MRK | NCT05239728 A Study of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Clear Cell Renal Cell Ca | Carcinoma, Renal Cell |
| 2026-10-28 est. | P3 | Albireo, an Ipsen Company | NCT05426733 An Open-label Extension Study to Evaluate Long-term Efficacy and Safety of Odevixibat in Children With Biliary Atresia | Biliary Atresia |
| 2026-10-28 est. | P3 | Akeso | NCT06617416 A Study of AK104 in Subjects With Unresectable Locally Advanced NSCLC | NSCLC (Non-small Cell Lung Cancer) |
| 2026-10-28 est. | P2 | Boehringer Ingelheim | NCT06722157 A Study to Test Whether BI 771716 Helps People With an Advanced Form of Age-related Macular Degeneration (AMD) Called Geographic Atrophy | Macular Degeneration, Age-related; Geographic Atrophy |
| 2026-10-29 est. | P3 | Novartis Pharmaceuticals NVS | NCT05653349 Study of Ianalumab Versus Placebo in Addition to First-line Corticosteroids in Primary Immune Thrombocytopenia (ITP) | Primary Immune Thrombocytopenia (ITP) |
| 2026-10-29 est. | P2 | RECORDATI GROUP | NCT05928390 Pasireotide s.c. in Patients With Post-Bariatric Hypoglycaemia | Post-Bariatric Hypoglycemia |
| 2026-10-29 est. | P3 | Hoffmann-La Roche | NCT06588855 A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants With Moderately to | Moderately to Severely Active Ulcerative Colitis |
| 2026-10-29 est. | P2 | Clear Scientific, Inc. | NCT06721494 A Single-Dose Study to Evaluate Safety and Efficacy of CS-1103 in Participants Receiving a Single Dose of Methamphetamine | Methamphetamine Intoxication; Methamphetamine Disorders; Methamphetamine Abuse |
| 2026-10-30 est. | P2 | Genzyme, a Sanofi Company | NCT02843035 Venglustat in Combination With Cerezyme in Adult Patients With Gaucher Disease Type 3 With Venglustat Monotherapy Extension | Gaucher Disease Type 1; Gaucher Disease Type 3 |
| 2026-10-30 est. | P1/P2 | Nouscom SRL | NCT04041310 Nous-209 Genetic Vaccine for the Treatment of Microsatellite Unstable Solid Tumors | Solid Tumor, Adult |
| 2026-10-30 est. | P3 | Pfizer PFE | NCT04657991 A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic Melanoma | Melanoma |
| 2026-10-30 est. | P3 | Laekna Limited | NCT04851613 Study to Evaluate Efficacy & Safety of Afuresertib Plus Fulvestrant in Patients With Locally Advanced or Metastatic HR+/HER2- Breast Cancer | Breast Cancer |
| 2026-10-30 est. | P3 | Vertex Pharmaceuticals Incorporated VERX | NCT05444257 A Study Evaluating the Long-term Safety and Efficacy of VX-121 Combination Therapy | Cystic Fibrosis |
| 2026-10-30 est. | P2 | Mirati Therapeutics Inc. | NCT05853575 Trial of Two Adagrasib Dosing Regimens in NSCLC With KRAS G12C Mutation (KRYSTAL 21) | Advanced Cancer; Metastatic Cancer; Malignant Neoplasm of Lung |
| 2026-10-30 est. | P1/P2 | Biotheus Inc. | NCT05918133 A Study of PM8002 Plus Nab-paclitaxel as First Line Therapy for TNBC | TNBC |
| 2026-10-30 est. | P2 | Abbisko Therapeutics Co, Ltd | NCT06186804 A Phase II Study Evaluating the Efficacy and Safety of ABSK021 (Pimicotinib)) in the Treatment of cGvHD Chronic Graft Versus Host Disease (c | cGvHD |
| 2026-10-30 est. | P1/P2 | Tyligand Pharmaceuticals (Suzhou) Limited | NCT06385925 A Study of TSN1611 Treating Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation | Malignant Neoplasm |
| 2026-10-30 est. | P1/P2 | Shandong Suncadia Medicine Co., Ltd. | NCT06679036 A Trial of HRS-2189 in Combination With Fluvastatin±HRS-6209, or HRS-8080±HRS-6209, or HRS-6209+HRS-1358 in Breast Cancer Patients | Advanced Unresectable or Metastatic Breast Cancer |
| 2026-10-30 est. | P1/P2 | Shanghai Henlius Biotech | NCT06848699 A Phase Ib/II Clinical Study to Evaluate HLX43 in Combination With Serplulimab in Patients With Advanced/Metastatic Solid Tumors | Solid Tumor Cancer; Non Small Cell Lung Cancer |
| 2026-10-30 est. | P1/P2 | Antelope Surgical Solutions, Inc | NCT06906471 A Single-Arm, Blinded, Fluorescent PSMA Histopathology Trial of AS1986NS | Prostate Cancer; Prostate Cancer (Adenocarcinoma); Fluorescence Imaging |
| 2026-10-30 est. | P1/P2 | Nuwacell Biotechnologies Co., Ltd. | NCT06941350 A Trial to Evaluate the Safety and Efficacy of NCR102 in Subjects With aGVHD | Acute Graft-versus-Host Disease |
| 2026-10-30 est. | P2 | Innervate Radiopharmaceuticals LLC (Formerly: Illumina Radiopharmaceuticals LLC) | NCT06965621 18F-mFBG Imaging for Myocardial Sympathetic Innervation | Heart Failure; Ischemic Cardiomyopathy; ICD Patients |
| 2026-10-30 est. | P2 | Insud Pharma | NCT06968481 Sublingual Oxytocin for the Prevention of Post-partum Hemorrhage | Post Partum Hemorrhage |
| 2026-10-30 est. | P3 | CSPC Ouyi Pharmaceutical Co., Ltd. | NCT07026968 A Study of Prusogliptin Tablets Combined With Dapagliflozin Tablets and Metformin Hydrochloride Extended Release Tablets in Type 2 Diabetes | Type 2 Diabetes |
| 2026-10-30 est. | P1/P2 | Vidya Therapeutics Inc | NCT07085507 Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VT7208 in Healthy Participants and MS Patients | Multiple Sclerosis |
| 2026-10-30 est. | P2 | Innervate Radiopharmaceuticals LLC (Formerly: Illumina Radiopharmaceuticals LLC) | NCT07176286 18F-mFBG Cardiac Uptake With Lewy Body Dementia | Parkinson Disease (PD); Lewy Body Dementia (LBD) |
| 2026-10-30 est. | P2 | Jiangxi Kvvit Pharmaceutical Co., Ltd. | NCT07345390 Safety, Efficacy and Pharmacokinetic Characteristics of KR230109 Cream in Facial Acne Vulgaris | Acne Vulgaris |
| 2026-10-30 est. | P2 | Vincentage Pharma Co., Ltd | NCT07360275 A Study of VCT220 in Participants With Hypertension and Obesity or Overweight | Hypertension |
| 2026-10-30 est. | P3 | Kind Pharmaceuticals LLC | NCT07494409 A Study of AND017 to Evaluate Efficacy and Safety in Dialysis-Dependent Chronic Kidney Disease (DD-CKD) Patients With Anemia | Anemia Due to Chronic Kidney Disease |
| 2026-10-30 est. | P3 | Natureceuticals Sdn Bhd | NCT07669467 Nuvastatic® Phase III Trial for Fatigue in Triple-Negative Breast Cancer | Fatigue Related to Cancer Treatment; Breast Cancer |
| 2026-10-31 est. | P1/P2 | Orion Corporation, Orion Pharma ORN | NCT03436485 Safety and Pharmacokinetics of ODM-208 in Patients With Metastatic Castration-resistant Prostate Cancer | Prostate Cancer Metastatic |
| 2026-10-31 est. | P2 | Astellas Pharma Global Development, Inc. | NCT03816163 A Study of Zolbetuximab (IMAB362) in Adults With Pancreatic Cancer | Pancreatic Cancer; Metastatic Pancreatic Cancer; Metastatic Pancreatic Adenocarc |
| 2026-10-31 est. | P3 | Sarepta Therapeutics, Inc. SRPT | NCT03992430 A Study to Compare Safety and Efficacy of High Doses of Eteplirsen in Participants With Duchenne Muscular Dystrophy (DMD) (MIS51ON) | Muscular Dystrophy, Duchenne |
| 2026-10-31 est. | P3 | Jiangsu HengRui Medicine Co., Ltd. | NCT04842617 Phase III Study ：SHR6390/Placebo Combined With Endocrine Therapy for the Adjuvant Treatment of Hormone Receptor Positive,Human Epidermal Rec | Hormone Receptor Positive,Human Epidermal Receptor 2 Negative, Node-positive, Hi |
| 2026-10-31 est. | P1/P2 | Adagene Inc ADAG | NCT05405595 ADG126 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid Tumors | Advanced/Metastatic Solid Tumors |
| 2026-10-31 est. | P1/P2 | LaNova Medicines Limited | NCT05518045 A Study of LM-108 as Monotherapy or in Combination With Antitumor Therapies in Subjects With Advanced Solid Tumors | Advanced Solid Tumor |
| 2026-10-31 est. | P2 | AskBio Inc | NCT05598333 Phosphatase Inhibition by Intracoronary Gene Therapy in Subjects With Non-Ischemic NYHA Class III Heart Failure | Congestive Heart Failure |
| 2026-10-31 est. | P2 | MaaT Pharma | NCT05762211 Oral Pooled Fecal Microbiotherapy to Prevent Allogeneic Hematopoietic Cell Transplantation Complications (PHOEBUS Trial) | Transplant Complication |
| 2026-10-31 est. | P1/P2 | Xentria, Inc. | NCT05890729 Study of Multiple-Ascending-Dose Study of XTMAB-16 in Patients With Pulmonary Sarcoidosis With or Without Extrapulmonary Manifestations | Pulmonary Sarcoidosis |
| 2026-10-31 est. | P3 | Olema Pharmaceuticals, Inc. OLMA | NCT06016738 OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer | Breast Cancer; Advanced Breast Cancer; Metastatic Breast Cancer; ER Positive Bre |
| 2026-10-31 est. | P3 | Teva Branded Pharmaceutical Products R&D LLC | NCT06052267 A Study to Test if a Fixed-Dose Combination of Fluticasone Propionate/Albuterol Sulfate is Effective in Preventing Asthma Exacerbations | Asthma |
| 2026-10-31 est. | P1/P2 | Innovent Biologics (Suzhou) Co. Ltd. | NCT06083207 A Study of IBI3003 in Subjects With Relapsed or Refractory Multiple Myeloma | Multiple Myeloma |
| 2026-10-31 est. | P2 | NEXTGEN Bioscience | NCT06104839 Safety and Efficacy of Oral NXC-736 in Adult Participants With Moderate and Severe Alopecia Areata | Alopecia Areata |
| 2026-10-31 est. | P2 | Kyowa Kirin Co., Ltd. | NCT06116916 Study to Assess the Efficacy & Safety of KHK4951 in Patients With Diabetic Macular Edema | Diabetic Macular Edema (DME) |
| 2026-10-31 est. | P1/P2 | Shandong Suncadia Medicine Co., Ltd. | NCT06222879 Study of HRS-8080 or SHR-A2009 Combined With Anti-tumor Therapy in Patients With Unresectable or Metastatic Breast Cancer | Breast Cancer |
| 2026-10-31 est. | P2 | Salubris Biotherapeutics Inc | NCT06369298 Study of JK07 in Patients With Chronic Heart Failure | Heart Failure With Reduced Ejection Fraction; Heart Failure With Preserved Eject |
| 2026-10-31 est. | P2 | Genentech, Inc. | NCT06524375 A Study to Evaluate the Effect of Venetoclax on Participants Receiving a Covalent Bruton's Tyrosine Kinase Inhibitor (cBTKi) for First-line | Chronic Lymphocytic Leukemia |
| 2026-10-31 est. | P2 | Avistone Biotechnology Co., Ltd. | NCT06574347 Vebreltinib Plus PLB1004 as the First-line Therapy for Patients With EGFRm+/MET+ Locally Advanced or Metastatic NSCLC. | Non-Small-Cell Lung Cancer |
| 2026-10-31 est. | P2 | Amgen AMGN | NCT06593522 A Phase 2 Study of Anvumetostat in Participants With MTAP-deleted Advanced NSCLC (MTAPESTRY 201) | MTAP-deleted NSCLC |
| 2026-10-31 est. | P3 | AstraZeneca AZN | NCT06635447 Capivasertib+Fulvestrant asTreatment for Locally Advanced(Inoperable) or Metastatic HR+/HER2- Breast Cancer in Chinese Patients | Breast Cancer |
| 2026-10-31 est. | P3 | Longboard Pharmaceuticals | NCT06719141 A Study to Investigate LP352 in Children and Adults With Developmental and Epileptic Encephalopathies (DEE) | Developmental and Epileptic Encephalopathy |
| 2026-10-31 est. | P2 | Shanghai Henlius Biotech | NCT06742892 A Phase II Clinical Study to Evaluate HLX43 in Patients With Locally Advanced or Metastatic HCC Failed or Intolerance to Standard Therapy | Carcinoma, Hepatocellular |
| 2026-10-31 est. | P2 | Shanghai Henlius Biotech | NCT06769113 A Phase II Clinical Study to Evaluate HLX43 in Patients With Recurrent/Metastatic ESCC Failed or Intolerance to Standard Therapy | Esophageal Cancer |
| 2026-10-31 est. | P2 | Rhythm Pharmaceuticals, Inc. RYTM | NCT06772597 A Study of Setmelanotide in Patients With Prader-Willi Syndrome | Prader-Willi Syndrome; Obesity; Hyperphagia |
| 2026-10-31 est. | P2 | Topadur Pharma AG | NCT06954597 Safety and Tolerability of TOP-N53 Applied on Digital Ulcers in Patients With Systemic Sclerosis | Digital Ulcers in Systemic Sclerosis |
| 2026-10-31 est. | P2 | Haisco Pharmaceutical Group Co., Ltd. | NCT07019090 Long-term Safety and Efficacy Study of HSK44459 Tablets in Patients With Idiopathic Pulmonary Fibrosis (IPF) | Idiopathic Pulmonary Fibrosis (IPF) |
| 2026-10-31 est. | P2 | Animuscure Inc. | NCT07072195 A Study of AMC6156 in People With Sarcopenia | Sarcopenia in Elderly; Sarcopenia |
| 2026-10-31 est. | P2 | Spyre Therapeutics, Inc. SYRE | NCT07148414 A Study of SPY072 in Rheumatic Disease | Rheumatoid Arthritis; Psoriatic Arthritis; Axial Spondyloarthritis; Rheumatic Di |
| 2026-10-31 est. | P1/P2 | Myosin Therapeutics Inc. | NCT07185880 A Phase 1/2 Study of the Safety and Tolerability of MT-125 in GBM Patients | Glioblastoma (GBM) |
| 2026-10-31 est. | P3 | TG Therapeutics, Inc. TGTX | NCT07211633 A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, Radiological and Clinical Effects of Subcutaneous Ublituximab in Partici | Relapsing Multiple Sclerosis |
| 2026-10-31 est. | P2 | Neurimmune AG | NCT07213583 Study of Re-Treatment With ALXN2220 in Patients With ATTR-CM | Amyloid Transthyretin Cardiomyopathy |
| 2026-10-31 est. | P2 | Changzhou Qianhong Bio-pharma Co., Ltd. | NCT07396337 Study to Assess the Efficacy and Safety of QHRD106 Injection in Acute Ischemic Stroke. | Acute Ischemic Stroke |
| 2026-10-31 est. | P2 | Kadence Bio | NCT07434271 Study to Evaluate the Potential Effects of KH-001 on Intravaginal Ejaculatory Latency Time (IELT), Patient-Reported Outcomes, and Safety in | Premature Ejaculation |
| 2026-10-31 est. | P2 | Freya Biosciences ApS | NCT07453069 Effect of FB301 on Vaginal Bacterial Profile in Women With Asymptomatic Vaginal Dysbiosis Undergoing a Mock Frozen Embryo Transfer Cycle | Vaginal Dysbiosis |
| 2026-10-31 est. | P3 | Natureceuticals Sdn Bhd | NCT07669454 A Randomized, Double-blind, Placebo-controlled, Parallel-group, Comparative, Phase III Study to Evaluate the Efficacy and Safety of Nuvastat | Fatigue Related to Cancer Treatment; Colon Cancer |
| 2026-11 est. | P2 | BeiGene | NCT03736889 Tislelizumab (Anti-Programmed Cell Death Protein-1 (PD-1) Antibody) in MSI-H or dMMR Solid Tumors | MSI-H/dMMR Solid Tumors |
| 2026-11 est. | P1/P2 | Aptose Biosciences Inc. | NCT03850574 Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed | Leukemia, Myeloid, Acute; Refractory AML; Relapsed Adult AML; Myelodysplastic Sy |
| 2026-11 est. | P2 | BioNTech SE BNTX | NCT04486378 A Phase II Clinical Trial Comparing the Efficacy of RO7198457 Versus Watchful Waiting in Patients With ctDNA-positive, Resected Stage II (Hi | Colorectal Cancer Stage II; Colorectal Cancer Stage III |
| 2026-11 est. | P2 | AbbVie ABBV | NCT04895436 Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants Wi | Chronic Lymphocytic Leukemia (CLL) |
| 2026-11 est. | P1/P2 | BeOne Medicines ONC | NCT04973605 A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone | Relapsed/Refractory Multiple Myeloma |
| 2026-11 est. | P3 | Camurus AB | NCT05050942 A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With GEP-NET | Gastro-enteropancreatic Neuroendocrine Tumor |
| 2026-11 est. | P3 | Immunic AG IMUX | NCT05134441 Study to Evaluate the Efficacy, Safety, and Tolerability of IMU-838 in Patients With Relapsing Multiple Sclerosis | Multiple Sclerosis |
| 2026-11 est. | P3 | Immunic AG IMUX | NCT05201638 Study to Evaluate the Efficacy, Safety and Tolerability of IMU-838 in Patients With Relapsing Multiple Sclerosis | Multiple Sclerosis, Relapsing-Remitting |
| 2026-11 est. | P3 | NewAmsterdam Pharma NAMS | NCT05202509 Cardiovascular Outcome Study to Evaluate the Effect of Obicetrapib in Patients With Cardiovascular Disease | Atherosclerotic Cardiovascular Disease |
| 2026-11 est. | P1/P2 | Bexion Pharmaceuticals, Inc. | NCT05322590 BXQ-350 in Newly Diagnosed Metastatic Colorectal Carcinoma | Metastatic Colorectal Carcinoma; Neuropathy |
| 2026-11 est. | P2 | AbbVie ABBV | NCT05456685 Mirvetuximab Soravtansine (MIRV) With Carboplatin in Second-line Treatment of Folate Receptor Alpha (FRα) Expressing, Platinum-sensitive Epi | High Grade Ovarian Cancer; Primary Peritoneal Cancer; Fallopian Tube Cancer |
| 2026-11 est. | P2 | Pharmazz, Inc. | NCT05514340 Assess Safety and Efficacy of Sovateltide in Hypoxic-ischemic Encephalopathy | Hypoxic-Ischemic Encephalopathy; Neonatal Asphyxia; Neonatal Encephalopathy |
| 2026-11 est. | P1/P2 | Anbogen Therapeutics, Inc. | NCT05532696 Phase 1b/2 Study to Evaluate ABT-101 in Solid Tumor and NSCLC Patients | Advanced Solid Tumor; Non Small Cell Lung Cancer; HER2 Mutations |
| 2026-11 est. | P2 | IGC Pharma, LLC IGC | NCT05543681 Clinical Trial on Agitation in Alzheimer's Dementia | Alzheimer Disease; Agitation,Psychomotor; Care Giving Burden; NPS; Aggression |
| 2026-11 est. | P1/P2 | Tyra Biosciences, Inc TYRA | NCT05544552 Safety and Preliminary Anti-Tumor Activity of TYRA-300 in Advanced Urothelial Carcinoma and Other Solid Tumors With FGFR3 Gene Alterations | Locally Advanced Urothelial Carcinoma; Metastatic Urothelial Carcinoma; Solid Tu |
| 2026-11 est. | P2 | Stemline Therapeutics, Inc. | NCT05596409 ELACESTRANT in Women and Men With CDK4/6 Inhibitor-Naive Estrogen Receptor Positive, HER-2 Negative Metastatic Breast Cancer Study | Metastatic Breast Cancer |
| 2026-11 est. | P2 | Atossa Therapeutics, Inc. ATOS | NCT05607004 (Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Cancer | Breast Neoplasms; Invasive Breast Cancer; Estrogen-receptor-positive Breast Canc |
| 2026-11 est. | P2 | Beckley Psytech Limited | NCT05660642 An Open-Label Study to Evaluate the Safety, Tolerability and Pharmacodynamics of BPL-003 in Patients With Treatment Resistant Depression | Treatment Resistant Depression |
| 2026-11 est. | P1/P2 | Forge Biologics, Inc FIGP | NCT05739643 Gene Transfer Clinical Trial for Infantile and Late Infantile Krabbe Disease Treated Previously With HSCT | Krabbe Disease |
| 2026-11 est. | P2 | AbbVie ABBV | NCT05822752 Study to Evaluate Adverse Events, and Change in Disease Activity, When Intravenously (IV) Infused With Livmoniplimab in Combination With IV | Hepatocellular Carcinoma |
| 2026-11 est. | P1/P2 | Jiangsu HengRui Medicine Co., Ltd. | NCT06015048 A Trial of SHR-A1811 Combined With Other Antitumor Therapies in Advanced Solid Tumors. | HER2-expressing Advanced Solid Tumors |
| 2026-11 est. | P2 | TBF Genie Tissulaire | NCT06038331 Use of a Treated, Devitalized and Sterile Umbilical Cord Amniotic Membrane in the Treatment of STT Osteoarthritis | Osteoarthritis Hand |
| 2026-11 est. | P2 | Cardiff Oncology CRDF | NCT06106308 Study of Onvansertib in Combination With FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Beva | Metastatic Colorectal Cancer; CRC; KRAS/NRAS Mutation |
| 2026-11 est. | P2 | MediLink Therapeutics (Suzhou) Co., Ltd. | NCT06107686 A Study of YL202 in Selected Patients With Advanced Solid Tumors | NSCLC; Breast Cancer; HNSCC; Locally Advanced or Metastatic Solid Tumors |
| 2026-11 est. | P3 | CG Oncology, Inc. CGON | NCT06111235 A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT | Non Muscle Invasive Bladder Cancer; Urologic Cancer; Bladder Cancer; Urothelial |
| 2026-11 est. | P3 | Sichuan Baili Pharmaceutical Co., Ltd. | NCT06118333 A Study Comparing BL-B01D1 With Physician's Choice of Chemotherapy in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma(PANKU-N | Nasopharyngeal Carcinoma |
| 2026-11 est. | P2 | ReCode Therapeutics | NCT06237335 A Phase 2 Study Evaluating Safety and Tolerability of RCT2100 (CFTR mRNA) in Healthy Participants and in Participants With CF | Cystic Fibrosis |
| 2026-11 est. | P3 | medac GmbH | NCT06239311 Efficacy and Safety of Methotrexate Versus Placebo in Adults With Atopic Dermatitis. | Moderate to Severe Atopic Dermatitis |
| 2026-11 est. | P2 | argenx ARGX | NCT06284954 A Study to Evaluate Safety and Efficacy of Empasiprubart in Adults With Dermatomyositis | Dermatomyositis; Myositis |
| 2026-11 est. | P3 | Akeso | NCT06341335 A Study of AK104/Placebo Plus AK109/Placebo And Paclitaxel in Gastric or Gastroesophageal Junction Adenocarcinoma | Gastric and Gastroesophageal Junction Adenocarcinoma |
| 2026-11 est. | P2 | Ferrer Internacional S.A. | NCT06355531 A Study to Assess the Efficacy, Safety, and Pharmacokinetics of FNP-223 to Slow Progression of Progressive Supranuclear Palsy (PSP) | Progressive Supranuclear Palsy |
| 2026-11 est. | P3 | AbbVie ABBV | NCT06389136 A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab | Atopic Dermatitis |
| 2026-11 est. | P2 | Apogee Therapeutics, Inc. APOG | NCT06395948 A Study Evaluating APG777 in Atopic Dermatitis | Atopic Dermatitis |
| 2026-11 est. | P3 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. SKBBY | NCT06448312 A Study of SKB264 in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Locally Advanced or Metastatic Non-Small Cell Lung | Non-Small Cell Lung Cancer |
| 2026-11 est. | P2 | NewAmsterdam Pharma NAMS | NCT06496243 Impact of Obicetrapib and Obicetrapib Plus Repatha on Lp(a) Levels | Dyslipidemias |
| 2026-11 est. | P2 | Jiangsu HengRui Medicine Co., Ltd. | NCT06529432 A Study of Bupivacaine Liposome Injection in the Treatment of Pain After Thoracoscopic Surgery | Local Analgesia Via Nerve Block |
| 2026-11 est. | P2 | BeOne Medicines ONC | NCT06637501 A Study to Investigate Sonrotoclax Combined With Zanubrutinib Versus Zanubrutinib Alone in Participants With Previously Untreated Chronic Ly | Chronic Lymphocytic Leukemia |
| 2026-11 est. | P3 | Eli Lilly and Company LLY | NCT06662383 A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have Obesity | Obesity |
| 2026-11 est. | P2 | Sichuan Baili Pharmaceutical Co., Ltd. | NCT06668961 A Study of SI-B001+SI-B003 Combined With Platinum-based Chemotherapy as First-line Treatment in Patients With Recurrent or Metastatic Head a | Head and Neck Squamous Cell Carcinoma |
| 2026-11 est. | P2 | Calluna Pharma AS | NCT06736990 A Phase 2 Study of CAL101 in Patients With Idiopathic Pulmonary Fibrosis | Idiopathic Pulmonary Fibrosis |
| 2026-11 est. | P1/P2 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | NCT06737731 A Phase I/II Clinical Study of SHR-1681 for Injection in Patients With Advanced Solid Tumors | Malignant Solid Tumors |
| 2026-11 est. | P2 | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | NCT06767813 Clinical Study of TQB2868 Injection Combined With Anlotinib Capsule and Chemotherapy in the First-line Treatment of Metastatic Pancreatic Ne | Pancreatic Neoplasms |
| 2026-11 est. | P2 | Kiora Pharmaceuticals, Inc. KPRX | NCT06825702 Safety, Tolerability and Efficacy of Intravitreal KIO-104 in Patients With Macular Edema | Macular Edema |
| 2026-11 est. | P2 | ImmunityBio, Inc. IBRX | NCT06829823 Clinical Trial of Ablation Therapy in Participants With Intermediate-Risk Non-Muscle Invasive Papillary Bladder Cancer | Non-muscle Invasive Bladder Cancer (NMIBC) |
| 2026-11 est. | P2 | KeyBioscience AG | NCT06833749 Efficacy and Safety of KBP-336 in Obese Individuals with Osteoarthritis | Osteoarthritis in the Knee; Obesity |
| 2026-11 est. | P2 | Alkermes, Inc. ALKS | NCT06843590 A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Idiopathic Hypersomnia | Idiopathic Hypersomnia |
| 2026-11 est. | P2 | AbbVie ABBV | NCT06846320 Study to Assess Adverse Events and Change in Disease Activity When Oral ABBV-932 is Added to Antidepressant Therapies in Adult Participants | Generalized Anxiety Disorder (GAD) |
| 2026-11 est. | P3 | Sandoz | NCT06847724 Comparative PK, PD, Efficacy, and Safety Assessment of the Proposed Ocrelizumab Biosimilar CYB704 and Ocrevus in Participants With Relapsing | Relapsing Multiple Sclerosis |
| 2026-11 est. | P2 | Pacira Pharmaceuticals, Inc PCRX | NCT06884865 A Study to Assess Safety and Tolerability of PCRX-201 in Subjects With Painful Osteoarthritis of the Knee | Osteoarthritis (OA) of the Knee |
| 2026-11 est. | P3 | Eli Lilly and Company LLY | NCT06914895 A Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight | Type 1 Diabetes; Obesity; Overweight |
| 2026-11 est. | P3 | Eli Lilly and Company LLY | NCT06962280 A Long-Term Study of Tirzepatide (LY3298176) in Adults With Type 1 Diabetes and Obesity or Overweight | Type 1 Diabetes; Obesity; Overweight |
| 2026-11 est. | P2 | Reunion Neuroscience Inc | NCT07002034 RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical Illnesses | Adjustment Disorder |
| 2026-11 est. | P3 | DBV Technologies DBVT | NCT07003919 Safety Study of Viaskin® Peanut Patch in Peanut-Allergic Children 1 Through 3 Years of Age (COMFORT Toddlers) | Allergy; Peanut Allergy |
| 2026-11 est. | P3 | Wooshin Labottach Co., Ltd. | NCT07029516 Study to Assess Efficacy, Safety and Tolerability of a Nail Patch in Patients With Nail Fragility, Mychosis, Psoriasis | Nail Psoriasis; Nail Damage; Mycosis |
| 2026-11 est. | P2 | BRIM Biotechnology Inc. | NCT07078955 A Dose Regimen Study of BRM421 Ophthalmic Solution in Patients With Dry Eye Disease | Dry Eye Disease (DED); Keratoconjunctivitis Sicca |
| 2026-11 est. | P1/P2 | TYK Medicines, Inc | NCT07104643 Study of TYK-00540 Combined With Enzalutamide in Patients With Metastatic Castration-resistant Prostate Cancer（mCRPC） | mCRPC |
| 2026-11 est. | P2 | Arthrosi Therapeutics | NCT07116746 Evaluation of Efficacy and Safety of AR882 and XOI Co-administration in Uricase Treatment Failed Patients | Gout; Gouty Arthritis; Hyperuricemia; Gout Chronic; Refractory Gout; Uncontrolle |
| 2026-11 est. | P2 | Vir Biotechnology, Inc. VIR | NCT07142811 A Study to Evaluate Tobevibart+Elebsiran Versus Bulevirtide in Chronic HDV Infection | Viral Hepatitis |
| 2026-11 est. | P3 | Nanjing Chia-tai Tianqing Pharmaceutical | NCT07177859 A Phase III Study of NTQ5082 Capsules in the Treatment of Paroxysmal Nocturnal Hemoglobinuria Patients | Paroxysmal Nocturnal Hemoglobinuria |
| 2026-11 est. | P2 | SciNeuro | NCT07199777 A Phase 2a Study to Evaluate the Safety, Tolerability, and Efficacy of SNP318 in DME Patients | Diabetic Macular Edema; DME |
| 2026-11 est. | P2 | Eli Lilly and Company LLY | NCT07215312 A Study of LY3938577 in Participants With Type 2 Diabetes Previously Treated With Basal Insulin | Diabetes Mellitus, Type 2 |
| 2026-11 est. | P3 | Lynk Pharmaceuticals Co., Ltd | NCT07237568 A Study to Evaluate Efficacy and Safety of LNK01001 in Adults With Ankylosing Spondylitis | Ankylosing Spondylitis |
| 2026-11 est. | P3 | Verrica Pharmaceuticals Inc. VRCA | NCT07246590 Cantharidin Application in Patients With Common Warts (Verruca Vulgaris) (COVE-2) | Common Warts; Common Warts (Verruca Vulgaris); Human Papilloma Virus (HPV); Wart |
| 2026-11 est. | P3 | Waterstone Pharmaceutical (Wuhan) Co., LTD. | NCT07251309 A Two-Part, Phase 3 Study Evaluating the Efficacy and Safety of WS016 for the Treatment of Hyperkalemia | Hyperkalemia |
| 2026-11 est. | P2 | Bright Minds Biosciences Pty Ltd DRUG | NCT07266324 A 2-Part Study to Assess Efficacy, Safety and Tolerability of BMB-101 for the Treatment of Patients With Prader-Willi Syndrome. | Prader-Willi Syndrome |
| 2026-11 est. | P2/P3 | Nuance Hearing | NCT07282028 A Prospective, Open-label, Pivotal Study to Assess Spectacle Hearing Aid Safety and Efficacy | Hearing Loss Mixed |
| 2026-11 est. | P2 | Avistone Biotechnology Co., Ltd. | NCT07336732 Andamertinib With or Without Platinum-doublet Chemotherapy Versus Platinum-doublet Chemotherapy in Patients With NSCLC Harboring Atypical EG | Non-Small-Cell Lung Cancer |
| 2026-11 est. | P2 | Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. | NCT07398859 Clinical Study on TQH2722 Injection Combined With Background Therapy for Seasonal Allergic Rhinitis | Seasonal Allergic Rhinitis |
| 2026-11 est. | P2 | Shandong Suncadia Medicine Co., Ltd. | NCT07470983 A Phase II Clinical Study on the Efficacy and Safety of HRS-1780 in Participants With Primary Aldosteronism | Primary Aldosteronism |
| 2026-11 est. | P2 | Traws Pharma, Inc. TRAW | NCT07503405 Phase 2a Study of the Efficacy and Safety of TRX-100 in a Human Influenza A Challenge Model | Influenza |
| 2026-11 est. | P3 | Sinovac Biotech Co., Ltd SVA | NCT07505888 Phase Ⅲ Trial of Group ACYW135 Meningococcal Conjugate Vaccine in Children Aged 2-6 Years | Epidemic Meningitis; Meningococcal Vaccines |
| 2026-11 est. | P2 | Eli Lilly and Company LLY | NCT07511816 A Study of LY4515100 in Participants With Pain Following Third Molar Removal | Acute Pain; Molar; Molar, Third; Surgery, Oral |
| 2026-11 est. | P2 | NeuShen Therapeutics | NCT07521683 A Phase II Clinical Study to Evaluate the Efficacy and Safety of NS-136 in the Treatment of Schizophrenia | Schizophrenia(Acute) |
| 2026-11 est. | P2 | Haisco Pharmaceutical Group Co., Ltd. | NCT07551739 A Clinical Trial Evaluating the Efficacy and Safety of HSK55718 in Patients for Postoperative Pain Treatment in Orthopedic Surgery | Pain After Surgery |
| 2026-11 est. | P3 | Colgate Palmolive CL | NCT07605338 To Assess the Efficacy of Two Brushing Regimens: in the Reduction of Established Dental Plaque and Gingivitis. | Plaque, Dental; Gingivitis |
| 2026-11-01 est. | P2 | ML Bio Solutions, Inc. | NCT04800874 Study of BBP-418 in Patients With LGMD2I | LGMD2I |
| 2026-11-01 est. | P3 | Epygenix | NCT05066217 An Efficacy and Safety Study of Clemizole HCl in Patients With Lennox-Gastaut Syndrome | Lennox Gastaut Syndrome |
| 2026-11-01 est. | P1/P2 | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | NCT05584800 Study of ZGGS18 in Patients With Advanced Solid Tumors | Advanced Solid Tumor |
| 2026-11-01 est. | P3 | Scholar Rock, Inc. SRRK | NCT05626855 Long-Term Safety & Efficacy of Apitegromab in Patients With SMA Who Completed Previous Trials of Apitegromab | Spinal Muscular Atrophy; Spinal Muscular Atrophy Type 3; Spinal Muscular Atrophy |
| 2026-11-01 est. | P1/P2 | Corbus Pharmaceuticals Inc. CRBP | NCT06603844 First-in-human Study of CRB-601-01 to Treat Patients With Advanced Solid Tumor. | Solid Tumor |
| 2026-11-01 est. | P3 | Bristol-Myers Squibb BMY | NCT06951698 A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder | Bipolar-I Disorder With Mania or Mania With Mixed Features |
| 2026-11-02 est. | P2 | GlaxoSmithKline | NCT05723562 A Study of Dostarlimab in Untreated dMMR/MSI-H Locally Advanced Rectal Cancer | Neoplasms, Rectal |
| 2026-11-02 est. | P3 | AstraZeneca AZN | NCT06015737 A Phase III Study to Investigate the Efficacy and Safety of Anifrolumab in Adults With Chronic and/or Subacute Cutaneous Lupus Erythematosus | Cutaneous Lupus Erythematosus |
| 2026-11-02 est. | P2 | Regeneron Pharmaceuticals REGN | NCT06190951 A Trial to Learn if Fianlimab and Cemiplimab Are Safe and Work Better Than Anti-PD1 Alone in Adult Participants With Resectable Stage 3 or 4 | Melanoma |
Same data via CLI: bcf readouts search --upcoming 90; MCP tool readout_calendar. Source: ClinicalTrials.gov API v2 (NLM).